The prognosis of patients with non-small cell lung cancer (NSCLC) harboring oncogenic driver-gene alterations, such as epidermal growth factor receptor (EGFR) kinase mutation, anaplastic lymphoma kinase (ALK) fusion, c-ros oncogene 1 (ROS1) fusion, or rearranged during transfection (RET) fusion, those with pan-cancer harboring neurotrophic tyrosine receptor kinase genes 1/2/3 fusion, and those with cholangiocarcinoma harboring fibroblast growth factor receptor 2 (FGFR2) fusion has improved prominently with the introduction of molecularly targeted drugs. This evidence concerns the gene FGFR2 and non-small cell lung carcinoma.